HER2 in-Situ hybridization positive breast cancers with HER2/CEP17 ratio ≥2.0 and average HER2 copy number <4.0 are frequently discordant with HER2 immunohistochemistry results: Implications for potential modification of testing algorithm

被引：0
|
作者：
Livasy, Chad
Johnson, Nicole
Domfeh, Akosua
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Levine Canc Inst, Charlotte, NC USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-20-08
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
    Ji-Won Kim
    Jee Hyun Kim
    Seock-Ah Im
    Yu Jung Kim
    Hye-Suk Han
    Jin-Soo Kim
    Kyung-Hun Lee
    Tae-Yong Kim
    Sae-Won Han
    Yoon Kyung Jeon
    Do-Youn Oh
    Tae-You Kim
    In Ae Park
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 109 - 115
  • [32] Prognostic value of HER2/CEP17 ratio in HER2-positive early breast cancer by FISH testing
    Zheng, F.
    Du, F.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S155 - S155
  • [33] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
    Layfield, L. J.
    Schmidt, R.
    LABORATORY INVESTIGATION, 2012, 92 : 49A - 49A
  • [34] HER2/neu Gene Amplification Heterogeneity: The Significance of Cells With a 3:1 HER2/CEP17 Ratio
    Layfield, Lester J.
    Schmidt, Robert L.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (06) : 543 - 549
  • [35] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
    Layfield, L. J.
    Schmidt, R.
    MODERN PATHOLOGY, 2012, 25 : 49A - 49A
  • [36] Breast Cancers with HER2/CEP17 Ratio ≥2.0 and an Average HER2 Copy Number &lt; 4.0 per Cell: Clinicopathologic Features and Alternative Chromosome 17 Probe Analysis of 102 Cases from a Single Institution Study
    Bai, Qianming
    Zhou, Shuling
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [37] Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio &lt; 2, HER2 copy number ≥ 6): Are they mostly HER2 "positive?"
    Wei, Christina H.
    Yang, Lixin
    Stewart, Daphne
    Bedell, Victoria
    Schmolze, Daniel
    Apple, Sophia
    Murata-Collins, Joyce L.
    Pillai, Raju
    Mortimer, Joanne E.
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations
    Lambein, Kathleen
    Praet, Marleen
    Forsyth, Ramses
    Van den Broecke, Rudy
    Braems, Geert
    Matthys, Bart
    Cocquyt, Veronique
    Denys, Hannelore
    Pauwels, Patrick
    Libbrecht, Louis
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (03) : 200 - 207
  • [39] Breast Cancers with HER2/CEP17 Ratio ≥2.0 and an Average HER2 Copy Number &lt; 4.0 per Cell: Clinicopathologic Features and Alternative Chromosome 17 Probe Analysis of 102 Cases from a Single Institution Study
    Bai, Qianming
    Zhou, Shuling
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32
  • [40] The prognostic importance of high HER2 copy numbers and high HER2/CEP17 ratio in trastuzumab-treated early breast cancer
    Ronnlund, C.
    Robertson, S.
    Sifakis, E. G.
    Fredriksson, I.
    Foukakis, T.
    Hartman, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S614 - S614
12345